Dallas, Texas--(Newsfile Corp. - June 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners initiates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate reported 1Q25 results that highlight continued progress toward the commercial launch of its lead ADHD asset, CTx-1301. The Company remains focused on leveraging its proprietary Precision Timed Release (PTR) platform to address long-standing gaps in ADHD treatment. CTx- 1301 is uniquely designed to provide once-daily stimulant therapy with rapid onset and sustained efficacy through the entire active day, addressing limitations of existing therapies that often require booster doses. With a differentiated profile targeting an estimated $22B U.S. ADHD market, CING is actively preparing for commercialization while pursuing potential out-licensing opportunities outside the U.S. and initiating scale-up plans for a targeted product launch upon FDA approval.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Cingulate is on track to submit the NDA for CTx-1301 in mid-2025, including data from nine clinical trials.
• Pediatric and high-dose studies showed strong efficacy, safety, and flexible dosing for CTx-1301.
• The Company is actively preparing for U.S. launch and exploring out-licensing opportunities abroad.

Click image above to view full announcement.

About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255813